Clinical trial
The Effectiveness and Safety of Dupilumab in Children with Severe Asthma in China: a Real-world Study
NCT06851403 is registered in ClinicalTrials.gov with Guangzhou Institute of Respiratory Disease as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Effectiveness and Safety of Dupilumab in Children with Severe Asthma in China: a Real-world Study
- Lead sponsor
- Guangzhou Institute of Respiratory Disease
- Phase
- Observational
- Overall status
- Enrolling by invitation
- Start date
- January 30, 2022
- Completion date
- December 30, 2025
- Enrollment
- 213 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
asthma in children